The new anticoagulants dabigatran and rivaroxaban can be responsible for haemorrhagic
complications. As for any anticoagulant, bleeding management is challenging. We aimed to …

Introduction Anticoagulation therapies carry a risk of bleeding; reversal agents may be
beneficial in cases of severe bleeding even for anticoagulants with a relatively short half-life …

Background—Rivaroxaban and dabigatran are new oral anticoagulants that specifically
inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment …

The new oral anticoagulants dabigatran etexilate (Pradaxa), rivaroxaban (Xarelto), and
apixaban (Eliquis) have predictable pharmacokinetic and pharmacodynamic profiles and …

Unlike traditional anticoagulants, the more recently developed agents rivaroxaban,
dabigatran and apixaban target specific factors in the coagulation cascade to attenuate …

The direct thrombin inhibitor dabigatran and the anti-Xa agents rivaroxaban, edoxaban, and
apixaban are a new generation of oral anticoagulants. Their advantage over the vitamin K …

The new oral anticoagulants dabigatran, rivaroxaban and apixaban have advantages over
warfarin which include no need for laboratory monitoring, less drug–drug interactions and …

The new direct-acting anticoagulants such as dabigatran and rivaroxaban are usually not
monitored but may be associated with haemorrhage, particularly where renal impairment …

It was the objective of this study to quantify the effects of rivaroxaban administration on
global coagulation parameters associated with routine clinical procedures, we collected …

Purpose Available evidence on laboratory monitoring of coagulation assays and reversal
strategies for the management of hemorrhagic events associated with the newer …